WuXi Xpress White Paper: RNA therapeutics to become a dominant treatment modality within a decade

New Delhi, July 27, 2019: Industry experts speaking within a newly released WuXi Xpress White Paper on RNA have identified 2019 as potentially a key turning point for the modality, sparking the beginnings of a new era for RNA therapeutics.

After more than two decades of research, with Onpattro’s approval by both the US FDA and EU in 2018, the white paper suggests we may now see increasing numbers of therapies brought to patients. Especially, as many advances have been made in the last decade to make the delivery of RNAs more stable. In fact, more than 69 companies are now developing RNA therapeutics across some 315 clinical trials.

“Initially, DNA-based approaches were favored in drug development based on the inadequate delivery technologies for the less stable RNA. However, over the last ten years the field has seen major advances and RNA therapeutics offer a more flexible approach to address a variety of diseases compared to DNA-based therapeutics,” said MiNA Therapeutics CEO, Robert Habib, an expert contributor to the White Paper.

Corporate Comm India(CCI Newswire)